PresentationPresentation Combination therapy of immune checkpoint and nuclear export inhibitors in a renal cell carcinoma mouse model PDF (1.44 MB) Read MorePresentation High Throughput Screen to Evaluate Combinations With Ibrutinib in Various B-Cell Malignancies PDF (213.46 KB) Read MorePresentation Nuclear export inhibitor selinexor (KPT-330) demonstrates anti-tumor efficacy alone and in combination with chemotherapy in multiple breast cancer models PDF (589.47 KB) Read MorePresentation Assessing combinations of chemotherapy agents in Alveolar Soft Part Sarcoma cell lines PDF (1.89 MB) Read MorePresentation Melphalan and XPO1 Inhibition are Synergistic in Pre-Clinical Models of Multiple Myeloma PDF (266.69 KB) Read MorePresentation Phase 1 Study of Safety and Tolerability of Selinexor in Asian Patients with Advanced Solid Cancers PDF (772.77 KB) Read MorePresentation Selinexor, ARA-C and Idarubicin: An effective and tolerable combination in patients with relapsed, refractory AML: A multicenter phase II study PDF (318.03 KB) Read MorePresentation Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma PDF (3.98 MB) Read MorePresentation Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML PDF (923.48 KB) Read MorePresentation Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) PDF (1.21 MB) Read More Previous 1 … 6 7 8 9 10 … 15 Next